News

CleanGo Innovations’ subsidiary Kubera Black Technology announces plans to acquire Italian specialty pharma company Freia Farmaceutici Srl, aiming to expand its European footprint and globalize Freia’s gynecology, gastroenterology, and pneumology portfolio.

Zuellig Pharma has expanded its regional partnership with Lundbeck to strengthen commercialisation and market access for neuro-psychiatric medicines across key Asian markets.

Grifols has obtained European Medicines Agency approval for the entire plasma-derived medicines value chain of Grifols Egypt, creating a new EMA-compliant manufacturing and supply platform that can serve European markets and strengthen regional plasma sourcing and fractionation capacity.

China's innovative drug sector achieved a historic breakthrough in 2025 with over $100 billion in out-licensing deals, including massive partnerships with Pfizer, GSK, and Takeda, signaling its rise as a global pharma innovator.[1]

Hansa Biopharma has announced a strategic reorganisation of its European and international organisation to sharpen market access, commercial focus, and operational efficiency across its rare disease portfolio.

ProPharma has inaugurated a new office in Hyderabad, India, to expand its pharmaceutical consulting, regulatory, and outsourcing support for Asia-Pacific drug developers and manufacturers.

The European Medicines Agency has published a revised EU guideline on stability testing for post‑approval variations, raising and clarifying CMC data expectations for marketing authorisation holders operating in Europe.

New industry analysis highlights Asia’s increasing dependence on China for pharmaceutical active ingredients, with implications for manufacturing resilience, sourcing strategy, and regulatory risk management across the region.

The European Union has agreed a new pharmaceutical framework that streamlines regulation and reinforces supply security mechanisms, reshaping the operating environment for drug manufacturers across Europe.

Pfizer has signed a licensing agreement worth up to US$2.1 billion with Fosun Pharma unit Yao Pharma for an oral GLP-1 obesity drug program, underscoring China’s rising role in global metabolic drug innovation and cross-border pharma partnering.